检查点抑制剂增强抗体药物偶联物的效力。
Checkpoint Inhibitors Boost Power of Antibody-Drug Conjugate.
出版信息
Cancer Discov. 2016 Feb;6(2):OF3. doi: 10.1158/2159-8290.CD-NB2015-172. Epub 2015 Dec 23.
Abstract
The antibody-drug conjugate T-DM1 spurs immune cells to infiltrate HER2-positive breast tumors in patients. Treating mice that carry breast tumors with T-DM1 improves survival, but the tumors suppress the infiltrating lymphocytes. Combining T-DM1 with checkpoint inhibitors that block CTLA-4 and PD-1 overcomes this effect, eliminating breast tumors from 95% of the mice.
摘要
抗体偶联药物 T-DM1 可促使免疫细胞浸润 HER2 阳性乳腺癌肿瘤。用 T-DM1 治疗携带乳腺癌肿瘤的小鼠可提高存活率，但肿瘤会抑制浸润的淋巴细胞。将 T-DM1 与阻断 CTLA-4 和 PD-1 的检查点抑制剂联合使用可克服这种作用，从而使 95%的小鼠的乳腺癌肿瘤消除。
Zotero 插件